Д.Гантуяа
Loading...
Товч нэр
Д.Гантуяа
Бүтэн нэр
Дорж Гантуяа
Латин нэр
Dorj Gantuya
Албан тушаал
Тэнхимийн эрхлэгч
Эрдмийн цол
Дэд профессор
Боловсролын зэрэг
Доктор (Ph.D)
Харьяалал
ORCID
Scopus Author ID
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial(Elsevier BV, 2025-11) ;Batmunkh, Tsetsegsaikhan ;Neal, Eleanor F G ;Amraa, Otgonjargal ;Mazarakis, NadiaAltangerel, BolorBACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia. METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. CLINICALTRIALS: gov Identifier: NCT05265065. RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported. CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial(2026) ;Batmunkh, Tsetsegsaikhan ;Neal, Eleanor Fg ;Amraa, Otgonjargal ;Mazarakis, NadiaAltangerel, BolorINTRODUCTION: COVID-19 boosters restore waning immunity. After demonstrating non-inferiority of 15 μg versus 30 μg BNT162b2 at 28 days in Mongolian adults, we assessed 24-month immunogenicity and safety. METHODS: In this randomised, controlled trial, adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were assigned (1:1) to 15 μg or 30 μg BNT162b2. Anti-spike IgG, surrogate virus neutralisation (sVNT) against Wuhan-Hu-1 and Omicron BA.1, and interferon-gamma (IFN-γ) release assays (Ag1/Ag2) were assessed to 24 months. SARS-CoV-2 infections and serious adverse events (SAEs) were recorded. ClinicalTrials.gov: NCT05265065. RESULTS: Of 601 participants, 520 (86.5%) completed follow-up. IgG and IFN-γ responses were comparable between arms at 24 months (IgG geometric mean ratio (GMR) 1.06 [95% CI 0.95-1.18]; Ag1 GMR 1.17 [95% CI 0.82-1.66]; Ag2 GMR 1.06 [95% CI 0.73-1.54]). Median sVNT inhibition remained high (Wuhan-Hu-1 88% [interquartile range (IQR) 86-90]; Omicron BA.1 85% [IQR 70-88]). Twenty-eight SARS-CoV-2 infections occurred. Fifty-three SAEs were balanced by study arm, and none were vaccine related. DISCUSSION: Equivalent immunity and safety from 15 μg and 30 μg BNT162b2 boosters support fractional dosing as a cost-saving strategy. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT05265065, identifier NCT05265065.Scopus© Citations 2
